SER News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SE

Mkt Cap

$44.5M

Volume

14.21K

Next Earnings

November 12th

Loading chart

SE

SERSerina Therapeutics, Inc.

SER

Pay with—

Available Balance0.00

SE

Mkt Cap

$43.7M

Volume

14.21K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development SummitSerina Therapeutics announced that its Chief Development Officer will present data on novel POZ-based lipid nanoparticles (LNPs) that overcome PEG immunogenicity issues. The company's POZ-lipid showed no antibody response in rat vaccine studies, unlike standard PEG-lipids which elicit immune responses. Serina is also advancing replacement ionizable lipids to address safety concerns in LNP formulations.GlobeNewswire Inc. · Apr 7, 2026

Serina Therapeutics to Present at the 38th Annual Roth ConferenceSerina Therapeutics, a clinical-stage biotech company, announced that CEO Steve Ledger will present at the 38th Annual Roth Conference on March 24, 2026. The company is developing its proprietary POZ Platform™ technology for drug optimization, with a focus on treating neurological diseases. Serina has a pipeline including SER-252 (POZ-apomorphine) for Parkinson's disease and has secured partnerships including a non-exclusive license agreement with Pfizer for lipid nanoparticle drug delivery applications.GlobeNewswire Inc. · Mar 24, 2026

Stock Market Today: Futures Drop Ahead Of 'Triple Witching' Session As Iran Threatens 'Zero Restraint'— FedEx, Super Micro In Focus (UPDATED)U.S. stock futures declined on Friday with major indices down slightly ahead of 'triple witching' expiration. FedEx surged 10.43% on better-than-expected earnings and raised guidance, while Super Micro Computer plunged 23.61% after its co-founder was charged in an alleged AI technology export scheme to China. Planet Labs soared 17.25% and Scholastic gained 10.54% on strong earnings. Geopolitical tensions with Iran and energy market disruptions added to market uncertainty.Benzinga · Mar 20, 2026

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's DiseaseSerina Therapeutics announced the first patient enrollment in its Phase 1b registrational trial of SER-252, an investigational apomorphine therapy for advanced Parkinson's disease. The trial, initiated in Australia, evaluates safety, tolerability, pharmacokinetics, and preliminary efficacy. The company remains on track for first patient dosing in Q1 2026 and has FDA alignment on its 505(b)(2) NDA registrational pathway.GlobeNewswire Inc. · Feb 19, 2026

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar EventSerina Therapeutics' CEO Steven Ledger will present at Tribe Public's webinar on February 4, 2026, discussing FDA initiatives and their impact on drug development. The company recently received FDA clearance for its SER-252 IND application for Parkinson's disease treatment and is initiating Phase 1b clinical activities in Australia.GlobeNewswire Inc. · Feb 3, 2026

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and InvestorsSerina Therapeutics introduces a comprehensive communications platform to provide transparent updates about its SER-252 Parkinson's disease trial, focusing on patient, clinician, and investor engagement.GlobeNewswire Inc. · Oct 8, 2025

Pet's Best Life Wins “Overall Dog Health Product of the Year” For Longevity15® In 2025 Pet Innovation AwardsPet's Best Life received the 'Overall Dog Health Product of the Year' award for Longevity15®, a supplement containing C15:0 that supports cellular health and longevity in dogs, developed in partnership with Seraphina Therapeutics.GlobeNewswire Inc. · Aug 13, 2025

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025Serina Therapeutics is developing a drug candidate, SER-252, designed to provide continuous dopaminergic stimulation for better symptom control in Parkinson's disease. The company's proprietary POZ Platform technology aims to improve the safety, duration, and tolerability of Parkinson's treatments.GlobeNewswire Inc. · Jun 23, 2025

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42Serina Therapeutics, a clinical-stage biotech company, congratulates its strategic partner Juvenescence Ltd. on the $76 million first tranche close of its $150 million Series B funding and a new strategic partnership with M42, a global tech-enabled health company.GlobeNewswire Inc. · Jun 18, 2025

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42Serina Therapeutics, a clinical-stage biotech company, congratulates its strategic partner Juvenescence Ltd. on securing $150 million in Series B funding led by M42, a global tech-enabled health company. The partnership will establish a drug development hub in Abu Dhabi to accelerate the development of novel therapeutics.GlobeNewswire Inc. · Jun 17, 2025

to start trading

SE

SERSerina Therapeutics, Inc.

SER

Pay with—

Available Balance0.00

Your PositionYou don't own any SER yet.

Related Tickers

Earnings